| 5.30 Delayed Data As of Aug 16 |  -0.10 / -1.85%Today’s Change | 3.55 Today|||52-Week Range 20.18 | -48.94% Year-to-Date |
| Previous close | 5.40 |
| Today’s open | 5.33 |
| Day’s range | 5.27 - 5.43 |
| Volume | 27,563 |
| Average volume (3 months) | 110,956 |
| Market cap | $186.0M |
| Dividend yield | -- |
| Earnings growth (last year) | +78.54% |
| Earnings growth (this year) | +260.00% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +146.29% |
| P/E ratio | 108.3 |
| Price/Sales | 9.15 |
| Price/Book | 2.21 |
| Today’s change | Today’s % change | |
|---|---|---|
| PTGXProtagonist Therapeu... | -0.04 | -0.35% |
| ENZYEnzymotec Ltd | -0.65 | -8.23% |
| EVGNEvogene Ltd | -0.01 | -0.14% |
| ADVMAdverum Biotechnolog... | -0.26 | -5.46% |
| Last reporting date | May 6, 2016 |
| EPS forecast (this quarter) | $0.01 |
| Annual revenue (last year) | $59.9M |
| Annual profit (last year) | -$1.8M |
| Net profit margin | -0.41% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
President & Chief Executive Officer David A. Dresner |
Chief Operating Officer Frank D. Czworka |
Corporate headquarters Columbia, Maryland |
